Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.33 |
| ▸ | GSTK1 | Q9Y2Q3 | 2/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398591 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL398399 | 1.00 | PTGS2 (0.38) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL13216744 | 0.95 | PTGS1 (0.37) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL13685896 | 0.90 | PTGS2 (0.39) | PTGS2PTGS1LMNAMEN1BLM | |
| SCHEMBL23927587 | 0.90 | PTGS2 (0.39) | PTGS2PTGS1LMNAMEN1BLM | |
| Citric Acid SCHEMBL21682507 | 0.88 | ALDH1A1 (0.39) | PTGS2PTGS1 | |
| Citric Acid SCHEMBL23924223 | 0.88 | ALDH1A1 (0.39) | PTGS2PTGS1 | |
| SCHEMBL3232094 | 0.88 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL3239231 | 0.88 | PTGS2 (0.35) | PTGS2PTGS1 | |
| SCHEMBL5183160 | 0.83 | PTGS2 (0.35) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2911656-B1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2020-12-02 | — | — | EP | disclosed |
| WO-2018224419-A1 | NITRIC OXIDE DONATING ISOMANNIDE DERIVATIVES | NICOX S.A. (FR) | 2018-12-13 | — | — | WO | disclosed |
| CN-104994845-B | Quinonyl Nitric oxidedonating compounds for ophthalmic applications | 尼科斯科学爱尔兰公司 | 2017-11-17 | — | — | CN | disclosed |
| EP-2855464-B1 | NITRIC OXIDE DONOR NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9446015-B2 | Quinone based nitric oxide donating compounds for ophthalmic use | NICOX SCIENCE IRELAND (IE) | 2016-09-20 | — | — | US | disclosed |
| CN-104994845-A | Quinone based nitric oxide donating compounds for ophthalmic use | NICOX SA | 2015-10-21 | — | — | CN | disclosed |
| US-20150283106-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2015-10-08 | — | — | US | disclosed |
| EP-2911656-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | Nicox Science Ireland (IE) | 2015-09-02 | — | — | EP | disclosed |
| US-9079821-B2 | Quinone based nitric oxide donating compounds | NICOX SCIENCE IRELAND (IE) | 2015-07-14 | — | — | US | disclosed |
| US-9061962-B2 | Quinone based nitric oxide donating compounds | NICOX SCIENCE IRELAND (IE) | 2015-06-23 | — | — | US | disclosed |
| EP-1951653-B1 | SALICYLIC ACID DERIVATIVES | NICOX SA (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100210694-A1 | NEW NO-DONOR ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2010-08-19 | — | — | US | disclosed |
| US-20100210694-A1 | NEW NO-DONOR ASPIRIN DERIVATIVES | NICOX S.A. (FR) | 2010-08-19 | — | — | US | disclosed |
| WO-2010015447-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010014516-A1 | NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS | MERCK & CO., INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029678-A1 | DIURETICS | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| WO-2009150007-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-12-17 | — | — | WO | disclosed |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2009-05-07 | — | — | US | disclosed |
| US-20080293781-A1 | Salicylic Acid Derivatives | NICOX S.A. (FR) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029678-A1 | DIURETICS | NR3C2, REN, NR3C1 | PTGS2 1871/4885PTGS1 1395/4885LMNA 1975/4885 |
| US-20080293781-A1 | Salicylic Acid Derivatives | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885LMNA 3715/4885 |
| US-20100249189-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS1, NOS2 | PTGS2 105/4885PTGS1 56/4885LMNA 2520/4885 |
| US-20150283106-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NOS1, NOS3, NOS2 | PTGS2 56/4885PTGS1 31/4885LMNA 2979/4885 |
| US-20100210694-A1 | NEW NO-DONOR ASPIRIN DERIVATIVES | PTGIS, NOS2, NOS3 | PTGS2 7/4885PTGS1 5/4885LMNA 3769/4885 |
| US-20090118164-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | BMP2, SOST, BMP4 | PTGS2 1908/4885PTGS1 1676/4885LMNA 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.